Alpha Cognition
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
750 Pender St W 1200, Vancouver, British...Phone Number
(604) 564-9244Website
www.alphacognition.comRevenue
<$5 MillionStock Symbol
ACOGFIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alpha Cognition
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options.Explore more
Alpha Cognition Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alpha Cognition your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Alpha Cognition has new funding data
Earning: See what the market has to say on Alpha Cognition recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Alpha Cognition
Alpha Cognition, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Alpha Cognition launches new products
Click to see if Alpha Cognition had a recent Job posting/layoffs
Check if Alpha Cognition has recently received funding, and reach out quickly before it becomes old news!
Check out if Alpha Cognition is spiking on competitors!
Recommended Actions
Find VP level buyers at Alpha Cognition
Find more new buyers
Compare Similar Companies to Alpha Cognition
Compare insights from companies similar to Alpha Cognition, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2021
HC
Haley CarterOwner, Registered Physiotherapist, BHSc. MPT Certificate of Competency In Vestibular Rehabilitation
Company Profile Activity
Activity Insights
Alpha Cognition is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alpha Cognition is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alpha Cognition.
Alpha Cognition financials insights
Gather financial insights about Alpha Cognition, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$4.5M
Alpha Cognition Tech Stack
A closer look at the technologies used by Alpha Cognition
See more technologies
Most Recent Scoops
Project
Alpha Cognition has reported positive top-line results from the BEACON study, which demonstrated that following initiation of ZUNVEYL, providers observed improvements in cognition, neuropsychiatric symptoms, and activities of daily living, along with reductions in polypharmacy, in patients with mild to moderate Alzheimer's disease. Based on these findings, the company's medical team has submitted the data for presentation at several upcoming medical meetings.
Medical Research, Pharmaceuticals
Earnings
reported that approximately 76% of Q2 2026 ZUNVEYL writers placed repeat prescriptions, with productivity per writer rising to approximately six prescriptions per writer, indicating the product is transitioning from initial trial into routine clinical practice.
Pharmaceuticals, Clinical Operations
Project
Alpha Cognition has conducted more than 240 peer-to-peer programs since March 2026, reaching 1,058 attendees and 325 prescribers, and has maintained a scientific presence at key congresses including NADONA and NPA to support ZUNVEYL's real-world evidence program and strengthen payer and physician engagement.
Customer Engagement, Marketing Campaign, Medical Research, Pharmaceuticals
Earnings
Alpha Cognition has reported total operating expenses of $13.5 million for Q2 2026, comprising $11.5 million in SG&A and $2 million in R&D expense, reflecting continued investment in commercial infrastructure, payer engagement, marketing, and evidence-generation programs.
Earnings, Spending/Investment, Research & Development, Finance
Earnings
Pharmaceuticals
Alpha Cognition News & Media
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsHenry Du - VP of Finance & Accounting and Interim...Alpha Cognition (ACOG) Q4 2025 Earnings Transcript
Good afternoon, and thank you, everyone, for joining us today for Alpha Cognition's Fourth Quarter and Full Year Fiscal 2025 Results Call. Today, after the close of market, the company issued a press release announcing our financial results. Joining me on the call today are Alpha Cognition's Chief Executive Officer, Michael McFadden; and Chief Operating Officer, Lauren D'Angelo.Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call March 26, 2026 4:30 PM EDTCompany ParticipantsHenry Du - VP of Finance & Accounting and Interim...Alpha Cognition Q4 Earnings Call Highlights
Alpha Cognition (NASDAQ:ACOG) executives told investors the company is seeing continued sales growth and what it described as accelerating, durable adoption following the commercial launch of ZUNVEYL, an oral treatment approved for mild to moderate Alzheimer’s disease. Management emphasized early de
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Alpha Cognition
Sign Up For FreeTo access detailed company insights
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options.... Read More
